Audit: QRS - Angelica sinensis for Health & Longevity
Audit conducted on 16/08/2026 06:48 using AI4L / Opus 5
Summary
| Items | Count |
|---|---|
| Total | 93 |
| Passed | 83 |
| Failed | 0 |
| N/A | 10 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | Protocol, time-to-effect, benefit, risk, gate, marker and qualitative content all trace to ER lines 150–216, 236–297, 316–347, 369–393, 428–430, 454–477. |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | “Blood-thinner interaction unresolved” mirrors ER “neither established nor excluded” (line 501); “hormone-driven tumour growth seen in animals” preserves the animal-model limitation. |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | Pregnancy, warfarin-INR, platelet and transferrin thresholds carried at ER strength; “Tested alone, the root has repeatedly done nothing” matches ER line 499. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | Contraindications come only from the ER avoid list (lines 338–347) plus the ER bullet flagged “(absolute contraindication)”; interactions only from ER lines 318–336. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | No PMIDs, NCT identifiers, author names or brand names in the QRS; the formula names Danggui Buxue Tang / Danggui Shaoyao San / Danggui Sini appear in the ER for the same facts. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | All attributions (“the dose-escalation trial”, “the renal anemia meta-analysis”, “the glomerulonephritis trial”) are ER attributions for the same facts. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Sober, sceptical, formula-versus-root framing matches the ER throughout. |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Quantified doses, thresholds and marker ranges presented neutrally and actionably. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | Content is stated as evidence and thresholds, not as orders. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | Cadence and gate items are phrased descriptively (“the threshold below which the root is avoided”), not as instructions. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | No “recommended”, “advised” or “should” constructions in the document’s own voice. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person pronouns anywhere in the file. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | “International normalised ratio”, “estimated glomerular filtration rate” and “urine albumin-to-creatinine ratio” are spelled out; remaining technical terms are ER-native and unavoidable. |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Gate and tier items are noun phrases; sub-lines are one sentence. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | Confirmed — no “you”/”your”. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Biomarker panel, third-party-quality thresholds and interaction gates address a proactive self-managing reader. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | 12-week granule courses, split dosing, repeat lab panels and perioperative washout are presented without hedging on effort. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | No simplification toward casual consumers; assumes lab access and adherence. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | At-A-Glance foregrounds that the root alone is inert — the decision-relevant signal for a self-supplementing reader. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | “anti-aging” does not occur; the title uses “Health & Longevity”. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt. | 🟢 | Clinical register throughout; the two plainer terms in At-A-Glance (“painkillers”, “blood-thinner”) are ER wording (ER lines 42, 499, 501) and required by the At-A-Glance plain-language rule. |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” | 🟢 | All fixed strings present verbatim at lines 446, 492, 543, 574, 592, 616, 645, 649–651, 786 and in the tier <strong> labels. |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | 64 distinct data-qrs-var spans present with no duplicates: 4 header, 1 at_a_glance, 9 action, 9 time, 4 benefits, stop_items, caution_items, 4 risks, 24 marker, monitoring_cadence, 6 qualitative. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | The non-variable website="evidence_review", website="audit" and website="full_review" spans are untouched (lines 423, 426, 440). |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | No source ER section relied on by the QRS is empty. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | “Standard traditional protocol”, “Trial-derived supplement protocol”, “Single versus split dosing” and all monitoring marker names are ER labels verbatim (ER lines 371, 373, 383, 462–468). |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | Time-to-effect cell labels derive from the three clauses of the single ER “Time to effect” bullet (line 430), which the template’s three-cell structure requires. |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | No emoji characters anywhere in the file; tiering is carried by <strong> labels and the CSS palettes. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Every section is condensed to the template budget: tier lists collapse to one <li> per tier, gate items to single noun phrases, sub-lines to one sentence. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | Lines 2–14, immediately after the doctype on line 1. |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | Opening --- at line 3, closing --- at line 13; the preamble text sits on line 2. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | Enclosed in an HTML comment; no element echoes its values. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Only duration: "00:03" is quoted, and it contains a colon. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | Line 4: er_filename: angelica_sinensis_2026-0825-0535_Opus_ER.md. |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | Line 5: qrs_prompt_version: 26.7.02, matching the QRS.md version badge. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | Line 6: qrs_creation_date: 2026-0816-0627. |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | Line 7: qrs_creator_ai_nickname: Opus. |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | “Opus” — single word, no version. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | Line 8: qrs_creator_ai_fullname: Opus 5. |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | “Opus 5” — nickname plus version, no qualifier. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | Line 9 matches the on-disk filename exactly. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Re-verified across all eleven keys; only the colon-bearing duration is quoted. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | Line 22: “Angelica sinensis for Health & Longevity - Quick Reference Sheet”. |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | Line 417: “Angelica sinensis for Health & Longevity”. |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | Line 421: 08/16/2026, matching qrs_creation_date 2026-0816-0627. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | Line 425: “Opus 5”. |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | Header carries only the title and the template subline; the ER’s “Also known as” line is not carried over. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Condenses ER lines 499–503: formula-versus-root verdict, the three positive domains, the null single-herb result, and the two safety signals. |
| 7.2 | [at_a_glance] is no longer than 60 words | 🟢 | 58 words. |
| 7.3 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Each clause maps to a distinct Conclusion sentence (ER lines 499, 501). |
| 7.4 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | Plain renderings used throughout: “kidney-related anemia”, “lung scarring”, “breathing tolerance”, “blood-thinner”, “hormone-driven tumour growth”; no acronyms. |
| 7.5 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | No trial names, years or sample sizes. |
| 7.6 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | No numbers of any kind. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All nine items trace to ER lines 326 and 338–347. |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | All eight ER avoid-bullets are represented, plus the ER interaction bullet flagged “(absolute contraindication)” for tamoxifen and aromatase inhibitors. |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | Nine <li> elements at lines 577–587. |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | ER trailing rationales are stripped (“on uterotonic grounds”, “on absent-safety-data grounds”, “— drugs that shut down the body’s own estrogen production”). |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | “(letrozole, anastrozole)”, “particularly the first trimester”, “below 100 × 10⁹/L”, “two weeks before and after”, “above 45%” all retained. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER uses no ranking notation inside parentheses in this section. |
| 8.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. |
🟢 | The section is populated, and the ER does identify such populations. |
| 8.8 | If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All nine items trace to ER lines 318–336. |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | Nine of the ten ER interaction bullets carried; the tamoxifen / aromatase-inhibitor bullet is correctly excluded because it sits in Contraindications. |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | Nine <li> elements at lines 595–606. |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Every ER mechanism sentence is dropped; only the agent name and severity tag remain. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Drug lists and severity tags retained and merged into a single paren, e.g. “(apixaban, rivaroxaban, dabigatran; caution)”. |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER uses no ranking notation inside parentheses in this section. |
| 9.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. |
🟢 | The section is populated, and the ER does identify such interactions. |
| 9.8 | If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | Sourced from ER Therapeutic Protocol lines 371, 373, 383. |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | Dose form and range, the trial-derived effective dose and duration, and dosing frequency — the three bullets that determine what is actually taken. |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER names twelve protocol aspects; all three sets are used. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | All nine action spans carry ER-derived content (lines 450–487 of the QRS). |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | Menstrual pain (1–3 cycles), anemia and kidney measures (12–24 weeks), and the eight-week minimum — the three clauses of ER line 430. |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Menstrual pain is the ER’s only High-tier benefit and comes first; the Medium/Low kidney and anemia block follows; the general floor is last. |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | Three distinct aspects exist and all three sets are used. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | All nine time spans populated; sub-lines name the ER studies that set each window. |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | The ER provides time-to-effect information at line 430. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | All ten ER benefit headings (lines 154–216) are represented in their original tiers. |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four spans present at lines 545, 548, 555, 562. |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Each item is the bare ER benefit heading; no magnitude or mechanism text carried over. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses in any benefit item. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four tiers carry items in the ER. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | All nine ER risk headings (lines 240–296) are represented in their original tiers. |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four spans present at lines 618, 621, 627, 634. |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Each item is the bare ER risk heading; no magnitude text carried over. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses in any risk item. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four tiers carry items in the ER. |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | Marker names, targets and rationales are taken verbatim from the ER Monitoring Protocol & Defining Success table (lines 460–468) and its baseline paragraph (line 456). |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All seven table biomarkers plus platelet count, which the ER names in the baseline paragraph (“antiplatelet users a platelet count”, line 456). |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | Line 776 condenses ER line 458 (warfarin 1/2/4 weeks then quarterly and after stopping; everyone else 12 weeks then 6-monthly). |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | Sourced from the ER qualitative-marker list at lines 472–477. |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All six ER qualitative markers are carried verbatim into qualitative_item_1 through qualitative_item_6. |
Issues 16/08/2026 06:48
Pass rate 100.00%. No issues found.
Issues 16/08/2026 06:40
- 14.2 — Platelet count marker missing: The ER
Monitoringsection names a platelet count as the baseline measurement for antiplatelet users (ER 456) and sets a numeric threshold of 100 × 10⁹/L (ER 345), but the QRS monitoring table (lines 649–751) omits it and lists only the seven markers from the ER’s table. - 11.4 — Time-to-effect subs restate value: [time_1_sub] (line 504) and [time_2_sub] (line 515) repeat their own label and value word for word (“Menstrual pain … one to three cycles”, “Anemia and kidney … 12 to 24 weeks”) and carry no content beyond them.
Fixes 16/08/2026 06:40
- 14.2 — Platelet count marker added: Added a
marker_8row to the monitoring table (Platelet count, “Above 100 × 10⁹/L”, “The baseline measure for antiplatelet users, and the threshold below which the root is avoided”), drawn from ER 456 and the 100 × 10⁹/L threshold at ER 345. - 11.4 — Time-to-effect subs rewritten: Replaced the two subs that merely restated their own label and value with their ER trial sources — [time_1_sub] now reads “Set by the pooled Danggui Shaoyao San and Danggui Sini decoction trials against analgesics” and [time_2_sub] “Set by the renal anemia meta-analysis and the 24-week proteinuria trial in glomerulonephritis”.
Issues 16/08/2026 06:32
- 9.5 — Interaction severity classes dropped: Six [caution_items] (QRS lines 590–600) drop the ER’s parenthetical severity class entirely — “(caution)” from direct oral anticoagulants, antiplatelet drugs, estrogen therapy and photosensitising drugs, and “(monitor)” from aspirin/NSAIDs, other blood-moving supplements and sedatives/alcohol — while warfarin and iron supplements retain theirs.
Fixes 16/08/2026 06:32
- 9.5 — Interaction severity classes restored: Re-added the ER’s parenthetical severity classes to the seven [caution_items] that had dropped them — “; caution” for direct oral anticoagulants, antiplatelet drugs and photosensitising drugs, “(caution)” for estrogen therapy and hormonal contraceptives, and “; monitor” / “(monitor)” for aspirin and NSAIDs, other blood-moving supplements, and sedatives and alcohol.